CN107648618A - 一种药物递送体系及其制备方法与应用 - Google Patents
一种药物递送体系及其制备方法与应用 Download PDFInfo
- Publication number
- CN107648618A CN107648618A CN201710891549.8A CN201710891549A CN107648618A CN 107648618 A CN107648618 A CN 107648618A CN 201710891549 A CN201710891549 A CN 201710891549A CN 107648618 A CN107648618 A CN 107648618A
- Authority
- CN
- China
- Prior art keywords
- drug delivery
- delivery system
- response
- molecule
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000012377 drug delivery Methods 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 62
- 229940079593 drug Drugs 0.000 claims abstract description 44
- 230000004044 response Effects 0.000 claims abstract description 42
- 239000002872 contrast media Substances 0.000 claims abstract description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 126
- 229920001184 polypeptide Polymers 0.000 claims description 83
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 83
- 150000001413 amino acids Chemical class 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 239000000758 substrate Substances 0.000 claims description 18
- -1 polymerase Proteins 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 102000050257 X-Linked Inhibitor of Apoptosis Human genes 0.000 claims description 7
- 239000000835 fiber Substances 0.000 claims description 7
- 230000014509 gene expression Effects 0.000 claims description 7
- 102000047934 Caspase-3/7 Human genes 0.000 claims description 6
- 108700037887 Caspase-3/7 Proteins 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- AOUOVFRSCMDPFA-QSDJMHMYSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O AOUOVFRSCMDPFA-QSDJMHMYSA-N 0.000 claims description 5
- 102000013382 Gelatinases Human genes 0.000 claims description 5
- 108010026132 Gelatinases Proteins 0.000 claims description 5
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 claims description 4
- 102000003902 Cathepsin C Human genes 0.000 claims description 4
- 108090000267 Cathepsin C Proteins 0.000 claims description 4
- 150000001735 carboxylic acids Chemical class 0.000 claims description 4
- 230000003439 radiotherapeutic effect Effects 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 108010065152 Coagulase Proteins 0.000 claims description 3
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 claims description 3
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 claims description 3
- 206010067125 Liver injury Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 210000005036 nerve Anatomy 0.000 claims description 3
- 230000002018 overexpression Effects 0.000 claims description 3
- 229920000151 polyglycol Polymers 0.000 claims description 3
- 239000010695 polyglycol Substances 0.000 claims description 3
- GBHSCKFAHCEEAZ-UHFFFAOYSA-N 2-[hydroxymethyl(methyl)amino]acetic acid Chemical compound OCN(C)CC(O)=O GBHSCKFAHCEEAZ-UHFFFAOYSA-N 0.000 claims description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims description 2
- 101710136259 E3 ubiquitin-protein ligase XIAP Proteins 0.000 claims description 2
- 102000004157 Hydrolases Human genes 0.000 claims description 2
- 108090000604 Hydrolases Proteins 0.000 claims description 2
- 108090000279 Peptidyltransferases Proteins 0.000 claims description 2
- 108010017842 Telomerase Proteins 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 230000005311 nuclear magnetism Effects 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims description 2
- 238000003746 solid phase reaction Methods 0.000 claims description 2
- 238000010671 solid-state reaction Methods 0.000 claims description 2
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical class C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
- 108090000992 Transferases Proteins 0.000 claims 1
- 102000004357 Transferases Human genes 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 238000002601 radiography Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 24
- 230000003902 lesion Effects 0.000 abstract description 15
- 231100000693 bioaccumulation Toxicity 0.000 abstract 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 42
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 239000011347 resin Substances 0.000 description 26
- 229920005989 resin Polymers 0.000 description 26
- 239000000243 solution Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 239000012216 imaging agent Substances 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 15
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 13
- 230000006870 function Effects 0.000 description 12
- 238000000746 purification Methods 0.000 description 11
- 238000010008 shearing Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 230000004224 protection Effects 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 7
- 239000003875 Wang resin Substances 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000002121 nanofiber Substances 0.000 description 7
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical group C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 108010075254 C-Peptide Proteins 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 235000021050 feed intake Nutrition 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 239000002086 nanomaterial Substances 0.000 description 6
- 238000001338 self-assembly Methods 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000000630 fibrocyte Anatomy 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 102100035716 Glycophorin-A Human genes 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 230000009514 concussion Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000007626 photothermal therapy Methods 0.000 description 4
- 238000004262 preparative liquid chromatography Methods 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010016555 SmacN7 peptide Proteins 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006482 condensation reaction Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 3
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 102100029855 Caspase-3 Human genes 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 238000005411 Van der Waals force Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- SEFVRKXJJPMVHQ-UHFFFAOYSA-N 2-[[2-[[2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]butanedioic acid Chemical compound NC(N)=NCCCC(NC(=O)CN)C(=O)NCC(=O)NC(CC(O)=O)C(O)=O SEFVRKXJJPMVHQ-UHFFFAOYSA-N 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical class ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 238000001142 circular dichroism spectrum Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002389 environmental scanning electron microscopy Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 108010078430 glutamine phenylacetyltransferase Proteins 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 239000002070 nanowire Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (9)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710891549.8A CN107648618B (zh) | 2017-09-27 | 2017-09-27 | 一种药物递送体系及其制备方法与应用 |
PCT/CN2017/106078 WO2019061561A1 (zh) | 2017-09-27 | 2017-10-13 | 一种药物递送体系及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710891549.8A CN107648618B (zh) | 2017-09-27 | 2017-09-27 | 一种药物递送体系及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107648618A true CN107648618A (zh) | 2018-02-02 |
CN107648618B CN107648618B (zh) | 2020-05-08 |
Family
ID=61116325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710891549.8A Active CN107648618B (zh) | 2017-09-27 | 2017-09-27 | 一种药物递送体系及其制备方法与应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN107648618B (zh) |
WO (1) | WO2019061561A1 (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108949147A (zh) * | 2018-06-22 | 2018-12-07 | 国家纳米科学中心 | 一种分子影像探针及其应用 |
CN110665016A (zh) * | 2019-10-25 | 2020-01-10 | 国家纳米科学中心 | 一种成像探针及其制备方法和应用 |
CN111603573A (zh) * | 2019-02-26 | 2020-09-01 | 国家纳米科学中心 | 一种spect分子影像探针及其制备方法和应用 |
CN112370533A (zh) * | 2020-08-24 | 2021-02-19 | 长沙理工大学 | 一种能长时间成像fap的生物发光探针及其应用 |
CN112979731A (zh) * | 2021-02-18 | 2021-06-18 | 郑州大学 | 一种活体自组装mri成像探针及其制备方法和应用 |
CN112999348A (zh) * | 2021-03-31 | 2021-06-22 | 西南交通大学 | 一种形貌可变的多肽-染料偶联物及制备方法与应用 |
CN113397032A (zh) * | 2021-05-24 | 2021-09-17 | 江苏省农业科学院 | 基于牛蒡糖蛋白的营养素递送体系及其制备方法和应用 |
CN114075266A (zh) * | 2020-08-13 | 2022-02-22 | 国家纳米科学中心 | 一种用于光热治疗的多肽组装单体及其制备方法和应用 |
CN118048050A (zh) * | 2024-04-16 | 2024-05-17 | 南京诺源医疗器械有限公司 | 一种七甲川菁近红外荧光染料及其制备方法和应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013036743A1 (en) * | 2011-09-09 | 2013-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Imaging agents for imaging protease activity and uses thereof |
CN104558107A (zh) * | 2013-10-09 | 2015-04-29 | 国家纳米科学中心 | 酶响应性的两亲性多肽和药物载体及其制备方法 |
CN104707150A (zh) * | 2013-12-11 | 2015-06-17 | 中国科学院上海药物研究所 | 肿瘤酶激活的量子点探针及其制备方法与用途 |
CN106084003A (zh) * | 2016-06-12 | 2016-11-09 | 国家纳米科学中心 | 基于细胞内酶催化聚合的多肽单体分子及其在构建纳米材料中的应用 |
CN106822036A (zh) * | 2016-12-15 | 2017-06-13 | 国家纳米科学中心 | 特异靶向多肽自组装纳米载体、载药纳米颗粒及制备方法 |
CN107137724A (zh) * | 2017-05-22 | 2017-09-08 | 国家纳米科学中心 | 一种细胞内构筑温度响应性聚集体的材料及其制备方法和应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004299501B2 (en) * | 2003-12-17 | 2010-12-23 | Wyeth Llc | Immunogenic peptide carrier conjugates and methods of producing same |
CN104894151A (zh) * | 2015-05-29 | 2015-09-09 | 扬州大学 | 一种刺激淋巴细胞活化的纳米基因药物及其制备方法 |
-
2017
- 2017-09-27 CN CN201710891549.8A patent/CN107648618B/zh active Active
- 2017-10-13 WO PCT/CN2017/106078 patent/WO2019061561A1/zh active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013036743A1 (en) * | 2011-09-09 | 2013-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Imaging agents for imaging protease activity and uses thereof |
CN104558107A (zh) * | 2013-10-09 | 2015-04-29 | 国家纳米科学中心 | 酶响应性的两亲性多肽和药物载体及其制备方法 |
CN104707150A (zh) * | 2013-12-11 | 2015-06-17 | 中国科学院上海药物研究所 | 肿瘤酶激活的量子点探针及其制备方法与用途 |
CN106084003A (zh) * | 2016-06-12 | 2016-11-09 | 国家纳米科学中心 | 基于细胞内酶催化聚合的多肽单体分子及其在构建纳米材料中的应用 |
CN106822036A (zh) * | 2016-12-15 | 2017-06-13 | 国家纳米科学中心 | 特异靶向多肽自组装纳米载体、载药纳米颗粒及制备方法 |
CN107137724A (zh) * | 2017-05-22 | 2017-09-08 | 国家纳米科学中心 | 一种细胞内构筑温度响应性聚集体的材料及其制备方法和应用 |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108949147B (zh) * | 2018-06-22 | 2021-02-09 | 国家纳米科学中心 | 一种分子影像探针及其应用 |
CN108949147A (zh) * | 2018-06-22 | 2018-12-07 | 国家纳米科学中心 | 一种分子影像探针及其应用 |
CN111603573A (zh) * | 2019-02-26 | 2020-09-01 | 国家纳米科学中心 | 一种spect分子影像探针及其制备方法和应用 |
CN111603573B (zh) * | 2019-02-26 | 2022-11-15 | 国家纳米科学中心 | 一种spect分子影像探针及其制备方法和应用 |
CN110665016A (zh) * | 2019-10-25 | 2020-01-10 | 国家纳米科学中心 | 一种成像探针及其制备方法和应用 |
CN114075266A (zh) * | 2020-08-13 | 2022-02-22 | 国家纳米科学中心 | 一种用于光热治疗的多肽组装单体及其制备方法和应用 |
CN114075266B (zh) * | 2020-08-13 | 2024-05-17 | 国家纳米科学中心 | 一种用于光热治疗的多肽组装单体及其制备方法和应用 |
CN112370533B (zh) * | 2020-08-24 | 2022-09-13 | 长沙理工大学 | 一种能长时间成像fap的生物发光探针及其应用 |
CN112370533A (zh) * | 2020-08-24 | 2021-02-19 | 长沙理工大学 | 一种能长时间成像fap的生物发光探针及其应用 |
CN112979731A (zh) * | 2021-02-18 | 2021-06-18 | 郑州大学 | 一种活体自组装mri成像探针及其制备方法和应用 |
CN112999348A (zh) * | 2021-03-31 | 2021-06-22 | 西南交通大学 | 一种形貌可变的多肽-染料偶联物及制备方法与应用 |
CN113397032A (zh) * | 2021-05-24 | 2021-09-17 | 江苏省农业科学院 | 基于牛蒡糖蛋白的营养素递送体系及其制备方法和应用 |
CN118048050A (zh) * | 2024-04-16 | 2024-05-17 | 南京诺源医疗器械有限公司 | 一种七甲川菁近红外荧光染料及其制备方法和应用 |
CN118048050B (zh) * | 2024-04-16 | 2024-06-25 | 南京诺源医疗器械有限公司 | 一种七甲川菁近红外荧光染料及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2019061561A1 (zh) | 2019-04-04 |
CN107648618B (zh) | 2020-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107648618A (zh) | 一种药物递送体系及其制备方法与应用 | |
US10111963B2 (en) | Nanoparticle drug conjugates | |
AU2002306500C1 (en) | Transporters comprising spaced arginine moieties | |
CN100548386C (zh) | 基于脂肪族生物可降解连接体的可释放的聚合物结合体 | |
CN102266288B (zh) | 一种基于胆固醇修饰的还原敏感性肿瘤靶向脂质体 | |
ES2349879T3 (es) | Peptidomiméticos fijados sobre patrón. | |
CN104288779B (zh) | 负载吉西他滨的peg化肽类树状大分子靶向给药***及其制备方法 | |
EP3459546B1 (en) | Multi-arm polymeric targeting anti-cancer conjugate | |
CN113599504B (zh) | 一种无载体蛋白质胞内递送前药及其制备方法与应用 | |
US20070140972A1 (en) | Targeting compositions and preparation therof | |
CN103768612B (zh) | 负载阿霉素的peg化肽类树状大分子靶向给药***及其制备方法 | |
CN107854693A (zh) | 整合素受体靶向的抗癌偶联物 | |
CN103768613B (zh) | 基于gflg的peg化肽类树状大分子给药***及其制备方法 | |
CN109069581A (zh) | 锁环螺旋肽及合成方法 | |
CN108714221A (zh) | 一种单抗类药物口服纳米制剂及其制备方法 | |
US9061069B2 (en) | Use of constrained peptide mimic oligomers as vectorization agents | |
CN101906143A (zh) | 两根Arg-Gly-Asp链通过Lys与一根脂肪醇链的偶联物、它们的合成及在医学中的应用 | |
CN108727584A (zh) | 抗癌偶联物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230105 Address after: No. 2, Ruitai Road, Huangpu District, Guangzhou, Guangdong 510700 Patentee after: Acep (Guangzhou) Biotechnology Co.,Ltd. Address before: 100190 No. 11, north of Haidian District, Beijing, Zhongguancun Patentee before: NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230725 Address after: Room E302-04, Innovation Building, No. 29, Shengshengyuan Road, Life Science Park, Changping District, Beijing 102200 Patentee after: Aisaipu (Beijing) Biotechnology Co.,Ltd. Address before: No. 2, Ruitai Road, Huangpu District, Guangzhou, Guangdong 510700 Patentee before: Acep (Guangzhou) Biotechnology Co.,Ltd. |